- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Diagnostic and Prognostic Biomarkers
During this opening segment of a one-on-one interview series, Peter Salgo, MD, discusses emerging diagnostic and prognostic biomarkers in prostate cancer with Ira M. Klein, MD, MBA, FACP, national medical director, clinical thought leadership, office of the chief medical officer at Aetna.
When patients with high PSA results undergo a biopsy, providers take into account several factors when deciding on treatment, including the patient’s Gleason score and tumor morphology, as well as the patient’s age and life expectancy, explains Dr Klein. He stresses the importance of emerging biomarkers, and notes that they may help providers determine how best to treat their patients. Unfortunately, there are currently no biomarkers with proven value in metastatic disease, comments Dr Klein.
Dr Klein is optimistic that ongoing trials will help establish the role of additional biomarkers that can help providers track disease progression and personalize treatment.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More
